Cotempla Xr-odt, Daytrana (methylphenidate) is a small molecule pharmaceutical. Methylphenidate was first approved as Cotempla Xr-odt on 2006-04-06. It is used to treat attention deficit disorder with hyperactivity, depressive disorder, and narcolepsy in the USA. The pharmaceutical is active against sodium-dependent dopamine transporter and sodium-dependent noradrenaline transporter. Ritalin's patents are valid until 2032-06-28 (FDA).
|Trade Name||Cotempla Xr-odt, Daytrana|
|Indication||attention deficit disorder with hyperactivity, depressive disorder, narcolepsy|
|Drug Class||Cns stimulant|